Skip to content

Sling versus sphincter for post prostatectomy incontinence

A comparison of the effectiveness of the Advance male sling and AMS 800 artificial urinary sphincter for mild to moderate post prostatectomy incontinence: a single-site, two-arm randomised controlled study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN55599282
Enrollment
50
Registered
2013-09-10
Start date
2013-02-08
Completion date
Unknown
Last updated
2019-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Generic Health Relevance and Cross Cutting Themes

Interventions

Advance Male Sling, Polypropylene mesh, retrourethral transobturator position. Inserted using two needle passers and through a perineal incision. Artificial Urinary Sp

Sponsors

University College London (UK)
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Post prostatectomy men at least 6 months after surgery 2. Mild to moderate stress urinary incontinence (mild 50-200 ml 1-2 pads/day; moderate 200-400 ml 3-4 pads/day) 3. Able and willing to participate in the study for its duration 4. Able to comprehend and complete health outcomes questionnaires 5. Able to understand instructions related to study procedures and give written informed consent 6. Target Gender: Male; Upper Age Limit 80 years ; Lower Age Limit 40 years

Exclusion criteria

Exclusion criteria: 1. Very mild incontinence (400ml; 5 pads or more; not appropriate for male sling) 3. Previous radiotherapy for prostate cancer 4. Previous surgery for post prostatectomy incontinence or urethral stenosis 5. Urodynamics showing detrusor overactivity or compliance loss deemed a significant contributor to incontinence, or bladder outflow obstruction 6. Any unstable serious coexisting medical condition(s)) including but not limited to: myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, cerebrovascular accident or uncontrolled diabetes or peptic ulcer disease which is uncontrolled by medical management within 6 months prior to Screening visit; which would preclude them from standard therapies as designated within the study design

Design outcomes

Primary

MeasureTime frame
Difference in 24 hour Pad weight; Timepoint(s): 3 months, 6 months, 12 months after surgery

Secondary

MeasureTime frame
Not provided at time of registration

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026